Poolbeg Pharma partner with Eurofins Genomics for AI data analysis (Interview)

Big data is transforming everything from the way we drive to the way we shop or even the way we consume energy. But when it comes to healthcare and fighting diseases, it still takes 10 or more

The future of drug discovery is no longer confined to the lab bench. It lies in the realm of intelligent algorithms, powerful computing, and the boundless creativity of generative AI. By embracing this technological leap, we

Like every year, 2024 kicked off with a bang for the biotech industry, as thousands gathered at the J.P. Morgan Health Conference (JPM) that took place in San Francisco, last week. One of the largest healthcare

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS).  

Despite advances in biotechnology, there are still more than 7,000 diseases today with no effective treatment. There also continue to be disparities in global health as treatments for many infectious diseases do not attract sufficient research

Poolbeg Pharma, a company focused on innovative medicines,m] has announced promising in vivo results for POLB 001 in treating cancer immunotherapy-induced cytokine release syndrome (CRS). The drug showed efficacy in significantly reducing the condition in an

2023 was the year of AI. It would be difficult to finish your day without seeing or hearing at least 5 updates about developments related to AI, ChatGPT or language models. The year was marked by

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas

In recent years, those applying computer science to biology have had no trouble raising the money to take their innovations straight into the commercial world. The promise was simple: get your hands on large datasets and

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Biopharmaceutical company Poolbeg has selected as strategic priority a number of potential treatments for Respiratory Syncytial Virus. The drug targets were selected from a list identified as part of Poolbeg’s artificial intelligence-led programme, which identified the

Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV). The programme identified the RSV drug treatment candidates in just 10 months, the company said

In the past year, generative artificial intelligence (GAI) has emerged as a potentially groundbreaking force in the pharmaceutical industry. This technology, which involves AI systems that can generate novel data and insights, could very well become

Advances in AI promise to transform drug discovery and development. AI not only brings more efficiency to today’s costly and slow processes but also holds the potential to identify entirely new drugs beyond the capabilities of